ODQ | CAS#41443-28-1 | sGC inhibitor

MedKoo Cat#: 561513 | Name: ODQ inhibitor

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ODQ potent and selective inhibitor of soluble guanylyl cyclase (sGC). The binding of ODQ is competitive with NO.

Chemical Structure

ODQ inhibitor

CAS#41443-28-1

Theoretical Analysis

MedKoo Cat#: 561513

Name: ODQ inhibitor

CAS#: 41443-28-1

Chemical Formula: C9H5N3O2

Exact Mass: 187.0382

Molecular Weight: 187.16

Elemental Analysis: C, 57.76; H, 2.69; N, 22.45; O, 17.10

Price and Availability

Size	Price	Availability
100mg	USD 850.00	2 Weeks
200mg	USD 1,350.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,250.00	2 Weeks
2g	USD 5,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ODQ;

IUPAC/Chemical Name

1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one

InChi Key

LZMHWZHOZLVYDL-UHFFFAOYSA-N

InChi Code

InChI=1S/C9H5N3O2/c13-9-12-7-4-2-1-3-6(7)10-5-8(12)11-14-9/h1-5H

SMILES Code

O=C1ON=C2N1C3=C(C=CC=C3)N=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor.

In vitro activity:

This study identified a compound, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), that potently and selectively inhibits NO-stimulated guanylyl cyclase activity. In incubated slices of cerebellum, ODQ reversibly inhibited the NO-dependent cGMP response to glutamate receptor agonists (IC50 approximately nM) but did not affect NO synthase activity. Reference: Mol Pharmacol. 1995 Aug;48(2):184-8. https://pubmed.ncbi.nlm.nih.gov/7544433/

In vivo activity:

In vivo, administration of lipoteichoic acid/peptidoglycan or lipopolysaccharide resulted within 6 hrs in hypotension, acute renal dysfunction, hepatocellular injury, and lung injury. Pretreatment of rats with ODQ attenuated the renal dysfunction, lung injury, and hepatocellular injury caused by lipoteichoic acid/peptidoglycan or lipopolysaccharide. Reference: Crit Care Med. 2001 Aug;29(8):1599-608. https://pubmed.ncbi.nlm.nih.gov/11505136/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	160.29
	DMF:PBS (pH 7.2) (1:1)	0.1	0.53
	DMSO	42.7	228.04
	Ethanol	0.5	2.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 187.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Haramis G, Zhou Z, Pyriochou A, Koutsilieris M, Roussos C, Papapetropoulos A. cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. Br J Pharmacol. 2008 Nov;155(6):804-13. doi: 10.1038/bjp.2008.312. Epub 2008 Aug 11. PMID: 18695639; PMCID: PMC2597233. 2. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995 Aug;48(2):184-8. PMID: 7544433. 3. Zacharowski K, Berkels R, Olbrich A, Chatterjee PK, Cuzzocrea S, Foster SJ, Thiemermann C. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001 Aug;29(8):1599-608. doi: 10.1097/00003246-200108000-00017. PMID: 11505136. 4. Fedele E, Jin Y, Varnier G, Raiteri M. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Br J Pharmacol. 1996 Oct;119(3):590-4. doi: 10.1111/j.1476-5381.1996.tb15713.x. PMID: 8894183; PMCID: PMC1915716.

In vitro protocol:

In vivo protocol:

1. Zacharowski K, Berkels R, Olbrich A, Chatterjee PK, Cuzzocrea S, Foster SJ, Thiemermann C. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001 Aug;29(8):1599-608. doi: 10.1097/00003246-200108000-00017. PMID: 11505136. 2. Fedele E, Jin Y, Varnier G, Raiteri M. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Br J Pharmacol. 1996 Oct;119(3):590-4. doi: 10.1111/j.1476-5381.1996.tb15713.x. PMID: 8894183; PMCID: PMC1915716.

1: Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995 Aug;48(2):184-8. PubMed PMID: 7544433. 2: Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996 Jul;50(1):1-5. PubMed PMID: 8700100.

View History

Purpuride

MedKoo CAT#: 145892

CAS#: 41411-07-8